In the BioHarmony Drug Report Database
Avatrombopag
Doptelet (avatrombopag) is a small molecule pharmaceutical. Avatrombopag was first approved as Doptelet on 2018-05-21. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. It is known to target thrombopoietin receptor. Doptelet’s patents are valid until 2025-05-05 (FDA).
Trade Name
|
Doptelet |
|---|---|
Common Name
|
avatrombopag |
ChEMBL ID
|
CHEMBL2103883 |
Indication
|
thrombocytopenia |
Drug Class
|
Thrombopoetin agonists |
Image (chem structure or protein)